Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Alto Neuroscience, Inc.

Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Announces $50 Million Private Placement Financing
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
From Alto Neuroscience, Inc.
Via Business Wire
Tickers ANRO
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.